{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:46:17Z","timestamp":1792896377425,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.eururo.2023.11.008","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T18:03:11Z","timestamp":1702404191000},"page":"242-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7458-7033","authenticated-orcid":false,"given":"Wolfgang","family":"Beckabir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara E.","family":"Wobker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Damrauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bentley","family":"Midkiff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"De la Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladmir","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Flick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Woodcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Bjurlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin G.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy L.","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Milowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.11.008_b0005","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"International collaboration of Trialists","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.11.008_b0010","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.11.008_b0015","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.clgc.2020.02.014","article-title":"Neoadjuvant gemcitabine-cisplatin plus radical cystectomy-pelvic lymph node dissection for muscle-invasive bladder cancer: a 12-year experience","volume":"18","author":"Iyer","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2023.11.008_b0020","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.11.008_b0025","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.11.008_b0030","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.11.008_b0035","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.11.008_b0040","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2023.11.008_b0045","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.11.008_b0050","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.21.01485","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm, phase II trial","volume":"40","author":"Funt","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.11.008_b0055","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1200\/JCO.21.01003","article-title":"Phase II study of gemcitabine and split-dose cisplatin plus pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive bladder cancer","volume":"39","author":"Rose","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.11.008_b0060","series-title":"Genitourinary Cancers Symposium","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","author":"Gupta","year":"2020"},{"key":"10.1016\/j.eururo.2023.11.008_b0065","series-title":"American Society of Clinical Oncology Genitourinary Cancers Symposium","article-title":"Safety and efficacy of perioperative cisplatin\/gemcitabine and durvalumab for operable muscle-invasive urothelial carcinoma: SAKK 06\/17","author":"Cathomas","year":"2021"},{"key":"10.1016\/j.eururo.2023.11.008_b0070","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.trecan.2022.02.007","article-title":"Tissue architecture in tumor initiation and progression","volume":"8","author":"Almagro","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.eururo.2023.11.008_b0075","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2023.11.008_b0080","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: accurate somatic small-variant calling from sequenced tumor\u2013normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.eururo.2023.11.008_b0085","article-title":"Calling somatic SNVs and indels with Mutect2","volume":"861054","author":"Benjamin","year":"2019","journal-title":"Biorxiv"},{"key":"10.1016\/j.eururo.2023.11.008_b0090","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.eururo.2023.11.008_b0095","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/bioinformatics\/btz033","article-title":"Improved indel detection in DNA and RNA via realignment with ABRA2","volume":"35","author":"Mose","year":"2019","journal-title":"Bioinformatics"},{"key":"10.1016\/j.eururo.2023.11.008_b0100","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.eururo.2023.11.008_b0105","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: efficient and comprehensive analysis of somatic variants in cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"10.1016\/j.eururo.2023.11.008_b0110","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","article-title":"Tumor mutational burden as a predictive biomarker in solid tumors","volume":"10","author":"Sha","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.eururo.2023.11.008_b0115","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2023.11.008_b0120","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1038\/s41467-022-33980-9","article-title":"Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer","volume":"13","author":"Damrauer","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2023.11.008_b0125","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/medicina57080769","article-title":"Neoadjuvant immunotherapy for muscle-invasive bladder cancer","volume":"57","author":"Peyrottes","year":"2021","journal-title":"Medicina"},{"key":"10.1016\/j.eururo.2023.11.008_b0130","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.eururo.2023.11.008_b0135","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41598-018-20282-8","article-title":"Optimized targeted sequencing of cell-free plasma DNA from bladder cancer patients","volume":"8","author":"Christensen","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2023.11.008_b0140","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.1038\/s41467-022-34251-3","article-title":"FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation","volume":"13","author":"Warrick","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2023.11.008_b0145","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1038\/s41467-018-05992-x","article-title":"EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer","volume":"9","author":"Wang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2023.11.008_b0150","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.11.008_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.996145","article-title":"Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: a comprehensive review","volume":"13","author":"Eskandari-Malayeri","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.eururo.2023.11.008_b0160","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.648187","article-title":"Fibroblast activation protein-\u03b1 as a target in the bench-to-bedside diagnosis and treatment of tumors: a narrative review","volume":"11","author":"Xin","year":"2021","journal-title":"Frontiers Oncol"},{"key":"10.1016\/j.eururo.2023.11.008_b0165","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.eururo.2023.11.008_b0170","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41374-020-0424-5","article-title":"Digital quantitative assessment of PD-L1 using digital spatial profiling","volume":"100","author":"Gupta","year":"2020","journal-title":"Lab Invest"},{"key":"10.1016\/j.eururo.2023.11.008_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v028.i05","article-title":"Building predictive models in R using the caret package","volume":"28","author":"Kuhn","year":"2008","journal-title":"J Stat Softw"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382303261X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382303261X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:14:17Z","timestamp":1759583657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382303261X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S030228382303261X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.11.008","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}